Drug Profile

Opaganib - RedHill Biopharma

Alternative Names: ABC-294640; YELIVA

Latest Information Update: 28 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Apogee Biotechnology Corporation
Developer Apogee Biotechnology Corporation; Medical University of South Carolina; RedHill Biopharma; University of Louisville
Class Adamantanes; Amides; Anti-inflammatories; Antihypoglycaemics; Antineoplastics; Antirheumatics; Antithrombotics; Antivirals; Chlorobenzenes; Obesity therapies; Pyridines; Small molecules
Mechanism of Action Sphingosine kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Neuroblastoma; Cholangiocarcinoma
New Molecular Entity Yes
Available For Licensing Yes - Cancer; Inflammation

Phase II/III COVID-19 pneumonia
Phase II Cholangiocarcinoma; Prostate cancer
Preclinical Ebola virus infections; Influenza A virus infections; Obesity; Radiation injuries; Renal fibrosis; Type 2 diabetes mellitus
Suspended Liver cancer
No development reported Acute radiation syndrome; Cancer; COVID 2019 infections; Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease; Solid tumours
Discontinued Multiple myeloma

28 Jul 2025 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia in Switzerland (PO)
28 Jul 2025 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia(Combination therapy) in Israel (PO)
28 Jul 2025 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com